Medical central enterprises have a big move

China Resources Shuanghe announced on the evening of February 23. In order to implement the companys 14th Five -Year Plan, further enrich the product line of the companys specialty field, improve the product matrix, and form "womens health+pediatrics"Specialty product sequences to enhance brand influence, the company intends to sign the" Equity Transfer Agreement about "to acquire 100%equity of China Resources Zizhu held by Bei Pharmaceutical Group.

The price of this transaction is based on the evaluation value.The evaluation value was 3.115 billion yuan.Based on the evaluation value of the total equity value of China Resources Zizhu, the total equity value of China Resources Zizhu. The price of 100%equity of China Resources Zizhu was 3.115 billion yuan, which was 170.40%of the value of 1.152 billion yuan from its single financial statements.

China Resources Zizhu has womens health medication and equipment, oral drugs, ophthalmology, medication, raw medicine and other product lines, reproductive health medicines to marketLater, he always occupied the important position of domestic and international markets. Yuting is a well -known brand of the company.

This transaction is an important measure for the integration of the China Resources Groups pharmaceutical sector business. By injecting high -quality assets into listed companies, in -depth promotion of strategic reorganization and professional integration, it will enrich China Resources ShuangheProduct lines in the field of specialty.

In 2022, China Resources Zizhu realized operating income of 959 million yuan, net profit of 269 million yuan, and 266 million yuan for non -net profit (unaudited).From January to August 2023, China Resources Zizhu realized operating income of 706 million yuan, net profit of 282 million yuan, and deducting non-net profit (unveiled) of 251 million yuan.

From the perspective of net interest rate, China Resources Purple Bamboo is more than twice that of China Resources Shuanghe, and the quality of assets is better.

Continuous mergers and acquisitions

Expand the non -infusion business

In recent years, through mergers and acquisitions integration, the non -infusion sector of China Resources Shuanghe is constantly developing.

In 2023, China Resources Shuanghe acquired 89.68%of Tianan Pharmaceuticals to enrich the companys diabetic drug product pipeline; in August 2022, the company announced the acquisitionEntering the field of biological fermentation, the company further acquired 31.25%of Tiandong Pharmaceuticals equity, realizing 70%of Tiandong Pharmaceutical Holdings to better integrate the companys resources and achieve better development in heparin anticoagulant areas.

In China Resources Shuanghe, Chinese ray and drug companies need to have international ability. It is difficult to form international competitiveness as a supporting agent.

Shenzhou Biological and Tiandong Pharmaceutical belong to relatively international companies.The international enterprise of CEP and the US EIR dual certificate, 70%of Shenzhou Bios business exported to the United States, Australia and other countries.Through the mergers and acquisitions of these two companies, China Resources Shuanghe will better improve its international network, further expand the export scale of the drug and drug, and drive the export of preparations through the export of raw materials.

In October 2022, Wang Xiangming, chairman of China Resources Group, pointed out during the survey of China Resources Shuanghe that in the next step, China Resources Shuanghe must unswervingly do innovative transformation.Pay attention to the improvement of investment mergers and acquisitions.

In August 2023, China Resources Shuanghe said in a survey of the institution that the company seized the industry integration window, developed around the field of expansion and capacity improvement, M & A steering and innovation direction, creating high -end imitation, first imitations, and innovative high -end technology platforms.The company is actively looking for a M & A target that meets the companys strategy.

In addition to the acquisition of China Resources Zizhu to enter the gynecology field, China Resources Shuanghe is still actively deploying, cooperating with enterprises to cooperate with enterprises, and expand the pediatric field to large pediatrics. At presentSome projects are under negotiation.

Edit: Joey

Review: Woodfish

Copyright statement

The China Fund News enjoys copyrights for the original content published on this platform, and reprints without authorization, otherwise it will be held accountable.

Authorized reprinting cooperation contact: Mr. Yu (Tel: 0755-82468670)